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ABSTRACT 
A significant proportion of men develop prostate cancer (PrCa) during their lifetime, 
which causes challenges for public health. PSA (prostate-specific antigen) screening 
studies have shown that testing all men at specific ages causes overdiagnosis of PrCa 
and unnecessary treatments for individuals who have indolent disease. Additional 
methods are required alongside PSA testing to be able to prognosticate the disease 
outcome and to focus the treatments on aggressive PrCa cases. The chromosomal 
location 2q37.3, where the transmembrane protein coding gene anoctamin 7 (ANO7) 
resides, is associated with PrCa susceptibility in linkage analyses and genome-wide 
association studies (GWAS). In addition, ANO7 has been considered to be expressed 
specifically in prostate tissue, and it has been suggested as a target for PrCa 
immunotherapy. 
This thesis work concentrates on investigating the role of ANO7 in PrCa. ANO7 
expression was significantly higher in prostate tissue than in any other tissue type, 
and ANO7 expression was elevated in PrCa compared to benign tissue. Moreover, 
elevated expression was associated with poor survival among patients. Next-
generation sequencing (NGS) analysis of the ANO7 gene revealed possible 
truncating rare germline variants, which were found only in PrCa patients and not in 
controls in the initial screening. These variants were genotyped from several 
different PrCa patient cohorts and sets of unaffected males. The stop-gain variant in 
exon 1 was associated with poor survival, and the variant in intron/exon 4 was 
associated with aggressive disease. Because the intron/exon 4 variant was related to 
aggressive cancer but not to poor survival, we investigated whether the variant 
carriers would have a good response to docetaxel treatment in castration-resistant 
PrCa. As was hypothesized, the variant carriers had a better response to docetaxel 
than the non-carriers. When investigating ANO7 protein interactions, we observed 
an enrichment specifically in proteins related to vesicle trafficking. This study 
indicates that ANO7 has a role in PrCa development and that truncating mutations 
in the gene predispose patients to aggressive PrCa. The variants reported in this study 
could facilitate precision medicine for PrCa patient care. 
KEY WORDS: ANO7, biomarker, castration-resistant prostate cancer, prostate 
cancer, protein-protein interaction   
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TIIVISTELMÄ 
Eturauhassyöpä on merkittävä kansanterveydellinen haaste, koska suuri osa miehistä 
saa taudin vanhetessaan. PSA-seulontatutkimukset ovat osoittaneet, että tietyn 
ikäisten miesten testaaminen aiheuttaa ylidiagnosointia ja turhia hoitoja niille, joiden 
syöpä ei etene aggressiiviseksi. Sen lisäksi, että hoitojen kustannukset 
terveydenhuoltojärjestelmälle ovat suuret, ylidiagnosointi aiheuttaa haittaa ja huolta 
myös itse potilaille. PSA-testauksen rinnalle tarvitaankin menetelmiä, joiden avulla 
potilaiden taudin ennustetta voidaan paremmin määrittää. Kromosomaalinen alue 
2q37.3, jossa solumembraaniproteiinia koodaava anoktamiini 7 (ANO7) sijaitsee, on 
yhdistetty eturauhassyöpään genominlaajuisissa assosiaatioanalyyseissa ja 
kytkentäanalyyseissa. ANO7-geenin on ajateltu ilmentyvän vain eturauhasessa ja sitä 
onkin ehdotettu eturauhassyövän immunoterapian kohteeksi. 
Tässä väitöskirjassa selvitettiin ANO7:n roolia eturauhassyövässä. Tutki-
muksessa selvisi, että ANO7 ilmentyy enemmän eturauhasessa kuin muissa kudok-
sissa ja enemmän syövässä kuin normaalikudoksessa. Voimakas ilmentyminen oli 
lisäksi yhteydessä lyhentyneeseen elossaoloaikaan. ANO7-geenistä löytyi uuden 
sukupolven sekvensointimenetelmällä proteiinille todennäköisesti haitallisia 
harvinaisia ituratavariantteja. Variantti eksonissa 1 oli yhteydessä lyhentyneeseen 
elinaikaan ja intronissa/eksonissa 4 oleva variantti assosioitui sairastumisriskiin ja 
aggressiiviseen tautiin. Koska intronin/eksonin 4 variantti oli yhteydessä aggres-
siiviseen tautiin, mutta ei lyhentyneeseen elinaikaan, tutkimme, hyötyvätkö variantin 
kantajat erityisen hyvin kastraatioresistentin syövän hoidossa käytettävästä 
docetaxel-lääkkeestä. Variantin kantajat saivat oletuksen mukaisesti paremman 
lääkevasteen. Kun tutkimme ANO7:n kanssa vuorovaikuttavia proteiineja, 
havaitsimme, että solujen vesikkeliliikenteeseen osallistuvat proteiinit olivat 
yliedustettuina. Tämä tutkimus osoittaa, että ANO7 on osallisena eturauhassyövän 
kehityksessä ja haitalliset geenivariantit altistavat aggressiiviselle eturauhassyövälle. 
Tutkimuksessa löydettyjä variantteja voidaan mahdollisesti hyödyntää 
tulevaisuudessa eturauhassyövän yksilöllistetyssä hoidossa. 
AVAINSANAT: ANO7, biomarkkeri, eturauhassyöpä, kastraatioresistentti etu-
rauhassyöpä, proteiini-proteiini -interaktio  
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GO Gene Ontology 
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GWAS Genome-wide association study 
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kDa Kilodalton 
LaPC Los Angeles Prostate Cancer-4 
LC-ESI-MS/MS  Liquid chromatography-electrospray ionization tandem 
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LNCaP Lymph node carcinoma of the prostate 
mCRPC Metastatic castration-resistant prostate cancer 
mRNA 
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NMD Nonsense-mediated decay 
OR Odds ratio 
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PARP Poly (ADP-ribose) polymerase 
PC3 Prostate cancer 3 
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PIN Prostatic intraepithelial neoplasia 
Pir Prostate cancer samples from Tampere University 
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PrCa Prostate cancer 
PrEC Prostate epithelial cell 
PSA Prostate-specific antigen 
PTEN Phosphatase and tensin homolog 
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RNA Ribonucleic acid 
SDS-PAGE  Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis 
 11 
SND1 Staphylococcal nuclease domain-containing protein 1 
SNP Single nucleotide polymorphism 
SNV Single nucleotide variant 
STED Stimulated emission depletion 
T cell  T lymphocyte 
TCGA The Cancer Genome Atlas 
TMPRSS2-ERG  Transmembrane protease serine 2:v-ets erythroblastosis 
virus E26 oncogene homolog 
TNM 
TP53                     
Tumour, node, and metastasis 
Tumour protein p53 
TPCC Turku Prostate Cancer Consortium 
VCaP Vertebral cancer of the prostate 
 
 
  
12 
List of Original Publications 
This dissertation is based on the following original publications, which are referred 
to in the text by their Roman numerals: 
I Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, 
Jambulingam D, Ettala O, Knaapila J, Boström PJ, Wahlström G, Sipeky C, 
Pursiheimo JP, Tammela T, Kellokumpu-Lehtinen PL; PRACTICAL 
Consortium, Fey V, Maehle L, Wiklund F, Wei GH, Schleutker J. ANO7 is 
associated with aggressive prostate cancer. Int J Cancer. 2018 Nov 
15;143(10):2479-2487. Doi: 10.1002/ijc.31746. Epub 2018 Sep 22. 
II Kaikkonen E, Ettala O, Nikulainen I, Taimen P, Lehtinen I, Boström P, 
Kellokumpu-Lehtinen PL, Schleutker J. ANO7 rs77559646 Is Associated 
With First-line Docetaxel Treatment Response in Metastatic Castration-
resistant Prostate Cancer. Anticancer Research. 2019 Oct;39(10)5353-5359. 
Doi:10.21873/anticanres.13728. 
III Kaikkonen E, Takala A, Pursiheimo J-P, Wahlström G, Schleutker J. The 
interactome of a prostate specific Anoctamin 7. (In press.) 
The original publications have been reproduced with the permission of the copyright 
holders. 
 
  13 
1 Introduction 
Prostate cancer (PrCa) is one of the most commonly diagnosed cancer types, but due 
to effective diagnostic methods and treatments, only a small proportion of cases are 
lethal. However, every year, more than 900 patients die of PrCa in Finland. To avoid 
these deaths, more effective tools are required to differentiate aggressive cases from 
indolent cases at the early stage of cancer. Clinical determinations i.e., tumour 
staging and grading, and prostate-specific antigen (PSA) measurement can confirm 
that the already advanced cases are aggressive, but they are not optimal for predicting 
aggressiveness at earlier stages of the disease.  
Another central challenge in the field of PrCa is to decide how the advanced 
cancer type should be treated. Some locally treated PrCa cases continue progressing, 
and the patients are often treated hormonally to prevent cancer growth. At some 
point, however, the cancer transforms into a castration-resistant form (castration-
resistant prostate cancer (CRPC)) and grows despite treatment. Currently, there are 
several treatment options for CRPC, but they are not durable. Different drugs are 
administered sequentially to prolong the survival time, and the treatment selection 
depends more on the patient condition and age than on tumour characteristics. On 
the other hand, it is known that the response to the first CRPC treatment is the 
strongest, which highlights the importance of selecting the most effective treatment 
option for each individual. 
Biomarkers, such as germline variants, are ideal for predicting cancer 
aggressiveness and treatment selection since they are easily and reliably detected in 
blood samples and remain static for the whole lifetime. 
ANO7 was selected for a more detailed analysis since it has been linked to PrCa 
susceptibility and has been reported to have prostate-specific expression. The aim of 
my thesis was to investigate the role of ANO7 in more detail and to identify germline 
variants that were associated with disease outcome and thus could predict cancer 
aggressiveness and possibly treatment effectiveness. In addition, the goal of this 
thesis was to reveal ANO7 protein-protein interactions to obtain information about 
the unknown function of the protein.
  14
2 Review of the Literature 
2.1 Prostate cancer 
2.1.1 PrCa epidemiology 
Prostate cancer (PrCa) is the most common cancer type among men in Finland, and 
the disease affects over 5,000 men annually (The Finnish Cancer Registry, 2016 
report). Although the mortality rate is relatively low (5-year survival rate  
of 92%), PrCa is still the second leading cause of cancer death among  
males, accounting for 900 deaths per year (The Finnish Cancer Registry, 
https://cancerregistry.fi/statistics/cancer-statistics, 2016 report). 
2.1.2 Risk factors 
The risk of having PrCa increases with age. Early-onset cases are usually more 
aggressive than late-onset cases (Grönberg and others 1994). 
According to the International Agency for Research on Cancer (World Health 
Organization), PrCa incidence is the highest in Oceania, followed by North America 
and Europe. By contrast, Asia and Africa have the lowest incidence rates. African 
American background is related to the highest PrCa prevalence. The reason why 
PrCa is more common in developed countries may depend not only on the genetic 
background but also on lifestyle factors and the more effective diagnostics in these 
countries. 
Lifestyle-related factors that predispose to PrCa include low physical activity 
and obesity (Kaaks and Stattin 2010; Keogh and MacLeod 2012), diets containing, 
for example, milk, fat and grilled meat (Chan and others 2005), and exposure to 
carcinogens such as cigarette smoke (Huncharek and others 2010). In addition, 
infections and prostate inflammation can predispose patients to PrCa (De Marzo and 
others 2003; Sutcliffe 2010). 
PrCa is one of the most heritable so-called common cancers, and genetic factors 
explain 58% of the risk (Hjelmborg and others 2014). At the greatest genetic risk are 
men who have an affected brother or father (Zeegers and others 2003). The risk is 
also higher if a man has several affected relatives. Additionally, Chen and others 
Review of the Literature 
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reported that familial PrCa was associated with a more aggressive phenotype than 
non-familial PrCa and an early-onset of disease (Chen and others 2008). 
2.1.3 Prostate anatomy, function and tumorigenesis 
The prostate surrounds the urethra and is located below the urinary bladder. The 
prostate consists of three parts: the peripheral zone, where the majority of prostate 
carcinomas originate from, the central zone, and the transitional zone, where 
hyperplasia commonly develops (McNeal 1988). Histologically, it consists of 
stromal tissue and glands. The prostatic ducts are formed by a double row of 
epithelial cells that consists of luminal and basal cell layers, and neuroendocrine cells 
(van Leenders and Schalken 2003) (Figure 1). The secretory luminal cells of the 
glands produce mucus, which is secreted via the duct lumen into the prostatic utricle 
(Figure 1). The mucus, produced by the prostate, forms most of the semen and its 
role is to make the semen more alkaline and protect sperm cells from the acidic 
vaginal environment. The prostate-specific antigen (PSA) is produced by the prostate 
to liquefy the content of the semen. PrCa can arise from any of these cell types, but 
most commonly, it starts from luminal or basal cells (adenocarcinomas). The 
neuroendocrine type of PrCa is much rarer and originates from the neuroendocrine 
cells. In this doctoral thesis, the focus is on prostate adenocarcinoma. 
Figure 1.  Prostate anatomy. The figure is modified from the illustration of 
https://www.earthslab.com/anatomy/urethra/. 
PrCa development is a multi-step process. First, the cells start to divide inside the 
prostate gland and form a pre-cancerous prostatic intraepithelial neoplasia (PIN) 
Elina Kaikkonen 
16 
lesion. In the next step, the cells invade out of the gland but are still localized only 
inside the prostate. If the cancer continues progressing, the cells can penetrate 
through the prostate capsule and spread into the nearby organs, i.e., seminal vesicles 
and the bladder, and eventually into lymph nodes and other organs (Shen and Abate-
Shen 2010). 
2.2 PrCa diagnostics 
PrCa does not necessarily cause any symptoms; alternatively, the symptoms are similar 
to other urinary problems, such as the symptoms of benign prostatic hyperplasia, 
including urinary problems, blood in the urine, pain, and erectile dysfunction. In cases 
in which the cancer has already metastasized to the bone, a pathological bone fracture 
or pain in bones can be the first symptoms. If there is a suspicion of cancer, the prostate 
is first palpated, and any anomalies in shape or size are examined. PSA is usually 
measured to estimate the probability of PrCa. An increased level is an indication for 
prostate imaging and possibly for fine needle biopsy. 
2.2.1 PSA measurement and prostate imaging 
PSA is used in PrCa screening. It is measured from blood serum, and it helps in 
deciding whether there is a need for core needle biopsies. PSA is a protein that is 
specifically produced in prostate tissue from the kallikrein 3 (KLK3) gene. The 
normal concentration for men between 40 and 49 years is <2.5 ng/ml, and for men 
over 70 years, it is <6.5 ng/ml. An elevated level can indicate prostate carcinoma, 
but an increase is not PrCa-specific (Stamey and others 1987). Earlier, when the 12-
core biopsies were taken systematically from the prostate, only 25% of patients with 
concentrations above normal but under 10 ng/mL had PrCa based on biopsy analyses 
(Greene and others 2013). Currently, imaging techniques such as multiparametric 
magnetic resonance imaging (MRI) and ultrasound are commonly used in order to 
target the biopsies to the suspected cancer sites. MRI imaging before the biopsy has 
been shown to increase the number of positive cancer findings to 38% 
(Kasivisvanathan and others 2018). The MRI results can be utilized for both 
targeting the biopsies and estimating the probability of clinically relevant PrCa. MRI 
imaging results are interpreted according to the Prostate Imaging – Reporting and 
Data System Version 2 (PI-RADS TM v2) (Weinreb and others 2016). The PI-RADS 
category 1 corresponds to very low risk, PI-RADS 2 low, PI-RADS 3 intermediate, 
PI-RADS 4 high, and PI-RADS 5 very high risk of having clinically significant 
cancer. PSA level generally increases during the ageing process. Determination of 
the portion of free PSA (unbound to proteins) can be utilized for PSA values below 
10 ng/mL to obtain more information about the likelihood of cancer.  
Review of the Literature 
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Systematic PSA measurement is recommended only for men who are at high risk 
of developing PrCa due to a family history of PrCa (Mottet and others 2017). An 
elevated PSA level alone cannot be used for diagnosing PrCa; prostate biopsy is also 
required. 
2.2.2 Tumour evaluation 
Most commonly, biopsies are taken from the visible lesions based on the imaging 
results. If there is no visible tumor, 12 biopsy sample cores are systematically taken 
from different parts of the prostate. The level of cell differentiation for 
adenocarcinomas is histologically evaluated using the Gleason grading system. The 
cancer grade can reach a value of 3, 4 or 5: a Gleason grade of 3 represents 
moderately differentiated adenocarcinoma and a grade of 5 represents poorly 
differentiated adenocarcinoma. Poor differentiation is, in turn, related to more 
aggressive PrCa. The Gleason score (GS) is determined by summing the most 
common and the second most common Gleason grades, and the score can therefore 
vary between six and ten. The GSs are further divided into five grade groups by ‘The 
International Society of Urological Pathology’ (ISUP) according to the risk for 
biochemical relapse after radical prostatectomy. GS 3+3=6 corresponds to the ISUP 
grade group 1, GS 3+4=7 to the ISUP grade group 2, GS 4+3=7 to ISUP  3, GS 8 to 
the ISUP 4 and GS 9 and 10 to ISUP 5  (Epstein and others 2016).  
2.2.3 Risk evaluation 
According to European Association of Urology (EAU) guidelines (Mottet and others 
2017), cancers are classified into three groups according to their risk for biochemical 
recurrence after primary treatment: low-risk, intermediate-risk, and high-risk.  In 
addition to the Gleason score and the ISUP grade grouping, the classification is 
dependent on the tumour stage (T), the presence of nodal or distal metastases (N and 
M) and the PSA level. Localized tumours with PSA below 10ng/ml and a Gleason grade 
under seven (ISUP 1) belong to the low-risk group, whereas localized tumours with a 
Gleason grade of 7 (ISUP 2 or 3) or PSA over 10 but under 20 ng/ml belong to the 
intermediate-risk group. If the cancer is locally advanced, the Gleason grade is greater 
than 7 (ISUP 4 or 5), or PSA is greater than 20 ng/ml, the tumour is classified into the 
high-risk group. This classification is utilized in predicting cancer aggressiveness and 
treatment selection. Furthermore, other factors influencing the decision include age and 
life expectancy, other diseases, and the patient’s own opinions.  
A recent study by Zelic and others compared the performance of different PrCa 
mortality prediction systems. They found that ‘The Memorial Sloan Kettering Cancer 
Center nomogram with the number of positive and negative cores as the additional 
Elina Kaikkonen 
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predictors in the model’ (MSKCC_cores) that takes into account the information about 
PSA, primary and secondary Gleason grades (<3 or ≥4), clinical tumour stage 
(T1/T2/T3+) and the number of the positive and negative cores, gives the best 
estimation of PrCa mortality. The other well-performing prediction systems in the 
study were ‘The UCSF Cancer of the Prostate Risk Assessment’ (CAPRA) and 
‘Cambridge Prognostic Groups’ (CPG) risk group systems.(Zelic and others 2019).  
2.3 PrCa treatment 
Figure 2 shows the stages and treatment options of PrCa. Low-risk patients are usually 
surveyed to avoid unnecessary treatments, whereas intermediate- and high-risk 
patients are treated with local therapy that can be combined with adjuvant therapy. 
2.3.1 Surveillance 
PrCa patients classified as low risk are recommended to be monitored rather than 
treated to avoid possible adverse effects (Mottet and others 2017). During active 
surveillance, PSA can be measured regularly, new biopsies can be taken, and the 
cancer can be treated if it progresses during the follow-up. If the life expectancy of 
the patient is relatively short, watchful waiting with fewer PSA measurements is also 
an option. 
2.3.2 Local therapy 
Cancers that are localized inside the prostate can be treated with prostatectomy (radical 
removal of the prostate) or radiotherapy, which can be combined with neoadjuvant 
therapies. Prostatectomy is recommended for intermediate- and high-risk patients if 
the life expectancy is >10 years (Gillessen and others 2018). Additional adjuvant 
androgen deprivation therapy (ADT) therapy is given in the presence of nodal 
metastases. Radiotherapy is usually recommended for those patients who have shorter 
life expectancy or if the patient is not suitable for prostatectomy. 
Other treatment options for localized PrCa include cryotherapy and the high-
intensity focused ultrasound HIFU method. 
2.3.3 Hormonal treatment of advanced PrCa 
The PSA level is measured postoperatively after local treatment(s) to determine 
whether the PrCa progresses despite treatment. An increased PSA after the nadir (the 
lowest PSA value after the treatment) is a strong indicator of advancing cancer. 
Huggins and Hodges reported in 1941 that prostate tumours were hormone-
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dependent and that castration reduced the size of PrCa tumours (Huggins and Hodges 
1941). Because both normal and cancerous prostate cells are androgen-dependent, 
castration or ADT is utilized to decelerate the growth of cancer cells. 
2.3.4 Treatment of CRPC and mCRPC 
Almost all hormonally treated PrCa patients develop castration resistance at some 
point, meaning that the cancer can grow independent from androgen ablation. The 
progression can be seen as either biochemical or radiological recurrence. The 
treatments aim at relieving symptoms and prolonging survival time rather than curing 
the cancer. Cytostatic drugs and second-generation androgen receptor (AR)-targeted 
therapies are often used sequentially when the disease continues progressing despite 
medication. The decision of which drugs are given and in which order is currently 
based on the patient’s clinical characteristics (Halabi and others 2014) – not on tumour 
characteristics or biomarkers. On the other hand, it is known that first-line CRPC 
therapy provides the best response, highlighting the importance of treatment selection. 
Taxanes (docetaxel and cabazitaxel) were approved for treating metastatic 
castration-resistant prostate cancer (mCRPC) in 2004 and 2010, respectively, by the 
U.S. Food and Drug Administration (FDA). Docetaxel was shown to improve the 
median survival time by over two months compared to mitoxantrone treatment 
(Tannock and others 2004), and after FDA approval, it has been widely used as first-
line chemotherapy. Cabazitaxel, in turn, is a second-line drug designed for CRPC 
and is used after docetaxel treatment (de Bono and others 2010). Taxanes prevent 
microtubule polymerization. Due to improper microtubule function, the cell is 
arrested at the G2/M checkpoint, which causes apoptotic cell death (Schutz and 
others 2014). The other possible effect of taxanes on PrCa cells is that they may 
disturb AR translocation into the nucleus (Zhu and others 2010), which further 
decreases the transcription of AR-targeted genes. However, taxanes cannot always 
be used for treating patients since they have many adverse effects, such as lowered 
blood cell counts, nausea and allergic reactions.  
The FDA first approved the second-generation antiandrogens enzalutamide and 
abiraterone acetate as second-line treatments for metastatic CRPC in 2011 and 2012, 
respectively. Later, they were approved for use as first-line CRPC treatments for 
asymptomatic or mildly symptomatic patients. Enzalutamide prevents AR 
translocation into the nucleus and inhibits AR-mediated transcription, and 
abiraterone inhibits intratumoural androgen biosynthesis and blocks AR activation 
(Helsen and others 2014). While taxanes have been the gold standard in mCRPC 
treatment, second-generation antiandrogens are currently preferred over taxanes as 
first-line therapy because they have fewer side effects. However, they are also much 
more expensive than taxane therapies. 
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Radium-223 is an approved therapy for patients with bone metastases who are 
not suitable for chemotherapy. 
If PrCa is diagnosed at the metastasized phase, it is castration-naïve, and it should 
be treated hormonally and preferably in combination with docetaxel therapy (Mottet 
and others 2017). Abiraterone and enzalutamide or other second-generation 
antiandrogens are not approved as compensated drugs for castration-naïve disease 
by the Social Insurance Institution of Finland (KELA). 
Figure 2.  Prostate cancer progression and treatment of patients diagnosed with localized PrCa. 
In addition, PrCa can be diagnosed as de novo metastatic, hormone-sensitive stage 
(not shown in the plot), which can be treated with docetaxel. The second-generation 
antiandrogens can be administrated either before taxanes, after docetaxel or as the only 
CRPC treatment. PARP inhibitor olaparib has proven effective for mCRPC patients with 
genetic alterations in BRCA1, BRCA2 or ATM DNA repair genes. All treatments are not 
necessarily given to the same patient. 
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2.4 Diagnostic PrCa tests and prognostic and 
predictive biomarkers 
PSA is the only biomarker commonly used in PrCa detection and follow-up. Due to 
the limitations of the PSA analysis, it has been of great interest to find cancer-specific 
biomarkers that would also help in predicting cancer aggressiveness and the most 
suitable treatments. Hugosson and others investigated whether all males should be 
PSA screened at a certain age to diagnose cancer cases at early stages and to prevent 
PrCa deaths. They reported that 570 men must be PSA screened to avoid one PrCa-
caused death, which may lead to overdiagnosis. In addition, the cost effectiveness of 
this kind of screening is rather weak. Thus, PSA is not recommended for screening 
alone (Hugosson and others 2019).  
Modern medicine is increasingly turning towards personalized patient care. 
Biomarkers can be roughly divided into metabolic biomarkers and proteins, tumour 
RNA-based markers, somatic DNA alterations detection from tumours, and germline 
DNA alteration investigation. At tissue level Alpha-methylacyl-CoA racemase 
(AMACR), tumor protein 63 (p63/p40) or cytokeratin 5/6 are utilized in order to 
differentiate the neoplastic changes from the benign ones. 
 Some biomarkers, for example, the PCA3 test (Bussemakers and others 1999), 
the four kallikreins test (Bryant and others 2015) and STHML3 (Grönberg and others 
2015) combine information about clinical variables and measurements and 
additionally over 200 single nucleotide polymorphisms (SNPs). The latter two 
promise to help predict cancer aggressiveness. Other biomarkers predicting cancer 
aggressiveness include the fusion gene of the transmembrane protease serine 2:v and 
ets erythroblastosis virus E26 oncogene homolog (TMPRSS2-ERG) (Kulda and 
others 2016; Nam and others 2007) and the androgen receptor splice variant 7 (AR-
V7) (Antonarakis and others 2014; Guo and others 2009). TMPRSS2-ERG fusion 
has been reported to serve as a prognostic marker for taxane resistance (Reig and 
others 2016), and AR-V7 has been reported as a marker of resistance to abiraterone 
and enzalutamide in CRPC (Antonarakis and others 2014). 
Among the known germline biomarkers, mutations in the BRCA2 DNA repair 
associated (BRCA2) gene seem to be the best predictive markers for cancer 
aggressiveness (Castro and others 2013). However, BRCA2 mutations are rare, and 
therefore, all mutations in the BRCA2 gene or even all mutations in the DNA repair 
pathway are often considered together as one score. Additionally, studies have 
indicated that BRCA2 mutations are even rarer in Scandinavians than in other 
populations (Ikonen and others 2003; Mayrhofer and others 2018). Recently, the 
carriers of mutations in the DNA repair pathway have been shown to benefit from 
abiraterone and enzalutamide (Antonarakis and others 2018) and poly (ADP-
ribose) polymerase (PARP) inhibitors (Mateo and others 2018). Thus far, the only 
predictive genetic markers that have been confirmed in clinical trial are alterations 
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in homologous recombination repair genes ATM serine/threonine kinase  
(ATM), BRCA1 DNA repair associated (BRCA1) and BRCA2 
(https://clinicaltrials.gov/ct2/show/NCT02987543). The carriers of these 
alterations clearly benefit from PARP inhibitor olaparib.  
2.5 PrCa genetics 
2.5.1 Tumour genome 
New technologies, such as high-throughput sequencing, have emerged as a new 
method for the genetic investigation of cancers. These methods are able to analyse 
DNA and RNA molecules simultaneously. Not only are they fast and accurate, but 
the costs are currently reasonable and allow the usage of these methods in both 
research and diagnostic settings. Sequencing can be conducted for germline DNA 
to screen for cancer susceptibility or inherited genetic changes that predispose to 
aggressive cancer, or alternatively, the tumour DNA and RNA can be sequenced. 
Large projects such as ‘the International Cancer Genome Consortium’ (ICGC) and 
‘The Cancer Genome Atlas’ (TCGA) have collected sequencing data from various 
cancer types to make the data available for researchers and clinicians. 
For cancerous transformation, the cell needs to change genetically. According to 
the Hallmarks of Cancer theory by Hanahan and others (Figure 3) for transformation 
from a normal cell to a cancer cell, the cell needs to be capable of escaping growth 
suppressors and cell death, retaining proliferative signalling, inducing angiogenesis, 
invading and metastasizing, promoting inflammation, modifying cellular energy 
systems and increasing genomic instability and mutation rates (Hanahan and 
Weinberg 2011). 
There are several types of genetic alterations. Chromosomal rearrangements 
include insertions (addition of chromosomal parts), deletions (removal of 
chromosomal parts), duplications (parts of the chromosome are duplicated), 
inversions (parts of the chromosomes are turned around), and translocations (parts 
of the chromosomes move into another position). Substitutions of one nucleotide 
are called single nucleotide variants (SNVs). They can occur in the non-coding or 
coding region of the gene. The nucleotide changes in coding regions can be 
synonymous (do not change the amino acid), missense (change the amino acid into 
another), or nonsense (change the amino acid into a premature stop codon) 
variants. The changes can be inherited in the germline, or alternatively, they can 
be somatic. 
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Figure 3.  Modified from Hallmarks of Cancer: The Next Generation (Hanahan and Weinberg 
2011). 
Genes related to cancer formation are traditionally divided into tumour suppressor 
genes or proto-oncogenes. The tumour suppressor genes are responsible for 
decelerating cell proliferation and division. Usually, one functioning copy of the 
gene is enough to protect the cells, and only a lack of both copies causes problems. 
Inherited mutations in tumour suppressor genes are much more common than 
mutations in proto-oncogenes, and they are – with some exceptions – inherited 
recessively. 
In hereditary cancers, a person has only one functional copy of the gene and is 
therefore more susceptible to cancer development. Knudson has described this 
phenomenon as the ‘two-hit hypothesis’ (Knudson 1971) (Figure 4). The heritable 
cancer types that develop in adulthood are commonly a result of recessive changes 
in tumour suppressor genes. 
Mutations in proto-oncogenes usually dominantly affect the growth and survival 
of mutated cells. In contrast to mutations in tumour suppressor genes, hereditary 
mutations in proto-oncogenes are rare. Somatic mutations in oncogenes, in turn, are 
common in cancers. 
DNA repair genes are classified as a separate group from tumour suppressor 
genes, and they play a central role in many hereditary cancers, including PrCa. Their 
responsibility is to correct DNA damage. Mutations in DNA repair pathway genes 
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are typically recessive. It is noteworthy that the majority of the identified PrCa 
susceptibility genes are involved in DNA repair. 
Figure 4. Knudson’s two-hit hypothesis. A patient with inherited cancer already has one 
nonfunctional copy of the gene and needs only one more mutation in order to develop 
cancer. 
Epigenetic changes do not alter the DNA sequence, but gene activity can be 
regulated by, for example, epigenetic DNA methylation and histone protein 
modifications. Hypermethylation (i.e., silencing of gene expression) is very common 
in the early stages of PrCa, whereas hypomethylation (i.e., improper gene activation) 
occurs in metastatic PrCa (Yegnasubramanian and others 2008). Another type of 
epigenetic regulation of gene expression can occur via histone modifications. 
Histone modification patterns have been suggested to correlate with PrCa outcome 
and contribute to intertumoural heterogeneity (Seligson and others 2005). 
2.5.2 Inherited PrCa susceptibility 
The traditional methods for detecting new germline risk genes for PrCa include 
genome-wide association studies (GWAS) and linkage analysis. Both analyses are 
used for identifying genomic locations related to PrCa. The main difference is that 
while linkage analysis is used in affected families to define which loci are inherited 
Review of the Literature 
25 
with the disease, GWAS is used for case-control or case-case analyses for non-related 
patients. More than 160 SNPs are related to PrCa susceptibility (Dadaev and others 
2018). In Finland, the most relevant PrCa susceptibility genes are reported to be 
RNASEL (Carpten and others 2002), which encodes the apoptosis-inducing protein 
ribonuclease L, CHEK2 (Seppälä and others 2003), which encodes a DNA damage 
checkpoint kinase, and HOXB13 (Laitinen and others 2013), which encodes a prostate-
specific transcription factor. The G84 variant in HOXB13 has the strongest impact on 
PrCa susceptibility, which has been continuously reported (odds ratio (OR) of 8.8) in 
Finnish PrCa patients (Laitinen and others 2013). Some of the most frequently reported 
PrCa susceptibility genes are listed in Table 1. The vast majority of these are DNA 
repair genes. Although the significance of the germline BRCA2 gene has been reported 
several times, mutations are relatively rare among PrCa patients (Edwards and others 
2003). Notably, in the Finnish population, BRCA2 gene alterations do not appear to 
play an important role in PrCa susceptibility (Ikonen and others 2003). 
Table 1.  Genes related to PrCa susceptibility and aggressive progression. 
GENE NAME MECHANISM OF 
ACTION 
PRCA SUSCEPTIBILITY RISK FOR 
AGGRESSIVE PRCA 
BRCA1 DNA repair Leongamornlert and others 
2012; Struewing and 
others 1997 
BRCA2 DNA repair Kote-Jarai and others 
2011; Struewing and 
others 1997  
Castro and others 2013; 
Pritchard and others 
2016; Robinson and 
others 2015  
HOXB13 Dual function as 
tumour suppressor 
and proto-oncogene 
Ewing and others 2012; 
Kote-Jarai and others 
2015; Laitinen and others 
2013; Xu and others 2013 
CHEK2 DNA repair and 
tumour suppressor 
Dong and others 2003; 
Pritchard and others 2016; 
Seppälä and others 2003  
Pritchard and others 
2016  
RNASEL Tumour suppressor Carpten and others 2002; 
Rökman and others 2002; 
Schaid 2004 
ATM DNA repair Angèle and others 2004 
MLH1 DNA repair Grindedal and others 2009 
MSR1 DNA repair Xu and others 2002 
MSH2 DNA repair Grindedal and others 2009 
ELAC2 Tumour suppressor Rökman and others 2001; 
Tavtigian and others 2001 
MSH6 DNA repair Grindedal and others 2009 
NBN DNA repair Cybulski and others 2004 
TP53 Tumour suppressor Stacey and others 2011 
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2.5.3 Germline mutations predisposing to aggressive PrCa 
Only a few of the variants that predispose to PrCa are associated with aggressive 
disease (Helfand and others 2015) (Table 1). According to the study by Pritchard 
and others, germline mutations in BRCA2 and CHEK2 are statistically significantly 
enriched in metastatic PrCa cases compared with nonmetastatic PrCa cases (5.3% 
vs. 0.3% and 1.9% vs. 0.6% of the cases, respectively) (Pritchard and others 2016). 
They also found that deleterious germline mutations in DNA repair genes are 
enriched among metastatic cases when compared to cases of localized disease 
(11.8% vs. 4.6%) (Pritchard and others 2016). Robinson and others, in turn, 
investigated germline variants from mCRPC patients and found that both BRCA2 
and BRCA1 were drivers in the development of castration resistance (Robinson and 
others 2015). Inherited BRCA2 mutations have also been associated with poor 
survival among PrCa patients (Castro and others 2013). 
2.5.4 Somatic mutations driving PrCa progression and the 
development of mCRPC 
Somatic mutations can be caused by radiation or chemicals, or they can arise 
spontaneously. The most central somatic mutations driving CRPC development are 
located in the genes tumour protein P53 (TP53), AR, phosphatase and tensin 
homolog (PTEN), RB transcriptional corepressor 1 (RB1), forkhead box A1 
(FOXA1), APC regulator of WNT signalling pathway (APC) and BRCA2 (Armenia 
and others 2018). Robinson and others similarly reported that the most frequently 
mutated genes in CRPC are AR, TP53, PTEN, APC and BRCA2, but they also found 
some additional drivers, such as alterations in the DNA repair genes BRCA1, ATM, 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA/B), and B-raf proto-
oncogene, serine/threonine kinase/ Raf-1 proto-oncogene, serine/threonine kinase 
(BRAF/RAF1) (Robinson and others 2015). 
AR mutations are very common in PrCa tumours and have a central role in the 
development of CRPC. To activate AR, a normally functioning AR needs 
testosterone or dihydrotestosterone ligand binding. After activation, AR moves to 
the nucleus, forms a homodimer and binds to androgen-responsive elements in the 
DNA. In CRPC, the AR signalling pathway can be activated despite castration, but 
in most cases, the tumour remains dependent on androgens (Attard and others 
2008). AR can be amplified (Visakorpi and others 1995), or androgens can be more 
effectively produced from cholesterol and weak adrenal androgens (Stanbrough 
and others 2006; Twiddy and others 2011). Alternatively, AR can be activated by 
ligands other than testosterone and DHT (Coutinho and others 2016). In addition, 
alterations in AR coactivators can affect the transcriptional activation of the 
receptor (Taylor and others 2010). However, some somatic AR mutations and AR 
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splice variants are known to cause androgen-independent AR activation and can 
thus prevent a treatment response to second-generation antiandrogens (Joseph and 
others 2013; Romanel and others 2015). AR signalling can additionally be 
activated by other signalling pathways, such as the phosphatidylinositol-4,5-
bisphosphate 3-kinase/AKT serine/threonine kinase 1 (PI3K/AKT) pathway (Wen 
and others 2000). 
Because cancer cells lack normal cell cycle control, they are genetically unstable. 
In addition to the substitutions of single nucleotides or structural changes, even the 
number of chromosomes can be altered. In PrCa, a well-characterized fusion of two 
genes is TMPRSS2-ERG fusion, which brings together an androgen-regulated 
TMPRSS2 gene promoter and the proto-oncogene ERG, which further leads to 
elevated expression of ERG (Tomlins and others 2005).  
A phenomenon called chromoplexy, which was first described in whole genome 
sequencing of PrCa cancer samples by Baca and others, is a common source of PrCa 
related chromosomal rearrangements. Such rearrangements involve several 
chromosomes at the same time and can simultaneously cause multiple deletions and 
translocations of DNA (Baca and others 2013). 
2.6 ANO7 and PrCa 
2.6.1 Anoctamin protein family and their roles in cancer 
The anoctamin protein family has ten members (ANO1-10) that are Ca2+-activated 
membrane proteins. Although the name anoctamin refers to eight transmembrane 
domains, recent studies have demonstrated that most anoctamins have ten 
membrane-penetrating domains (Bushell and others 2019; Feng and others 2019; 
Paulino and others 2017). 
Anoctamins have been reported to have various roles in cells. They are calcium-
activating chloride ion channels, phospholipid scramblases, proteins that tether 
calcium repositories near the membrane, or non-selective cation channels. Suzuki 
and others reported that consistent with earlier studies (Schroeder and others 2008; 
Yang and others 2008), ANO1 and ANO2 have Cl- channel functions, whereas the 
other anoctamins do not have Cl- channel functions (Suzuki and others 2013). 
Instead, they found that anoctamins 3, 4, 6, 7 and 9 are able to scramble 
phospholipids, whereas anoctamins 5, 8 and 10 lack these capabilities. However, 
other studies have suggest that ANO5 (Gyobu and others 2016) and ANO10 (Bushell 
and others 2019) have phospholipid scramblase activity. ANO3 (Huang and others 
2013), ANO4 (Reichhart and others 2019), ANO5 (Whitlock and others 2018), 
ANO6 (Scudieri and others 2015), ANO9 (Kim and others 2018) and ANO10 
(Bushell and others 2019) have been suggested to have an additional nonselective 
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cation channel function. Moreover, at least ANO4 and ANO8 can bind to the 
endoplasmic reticulum near the plasma membrane (Jha and others 2019; 
Kunzelmann and others 2019), and this binding can activate cellular signalling by 
regulating membrane receptors and bringing calcium depositories close to the 
plasma membrane (Manford and others 2012). 
The most extensively characterized members of the family are the Cl- ion channel 
ANO1 and the phospholipid scramblase ANO6. ANO1 is expressed in many 
secretory epithelial cells (Jang and Oh 2014), whereas a specific mutation in the 
ANO6 gene causes the abnormal blood clotting disorder Scott syndrome (Suzuki and 
others 2010). ANO5 mutations, in turn, are associated with muscular dystrophy 
(Liewluck and others 2013). Anoctamin proteins 1, 6, 7, 8, 9 and 10 are present in 
various epithelial cells, and they commonly localize on the apical side of polarized 
epithelial cells (Schreiber and others 2010). ANO2-5, in turn, are expressed in other 
cell types, such as neurons and muscle cells (Schreiber and others 2010). Anoctamins 
have varying localization between tissue types, but they also have different cellular 
localizations that can change depending on the cell stage or the type of cell 
(Kunzelmann and others 2019). 
Kunzelmann and others suggest that anoctamins have various roles in the plasma 
membrane: releasing exosomes (ANO1 and 6) and mucus (ANO1), regulating 
membrane protein expression (ANO1 and 6), modifying membrane curvature 
(ANO6), and promoting cell migration and metastasis formation (Kunzelmann and 
others 2019). ANO1 has been associated with several cancers, such as 
gastrointestinal stromal tumours (Miettinen and others 2009), head and neck cancer 
(Reddy and others 2016) and breast cancer (Britschgi and others 2013). As would be 
expected due to the fluctuating expression profiles and cellular localizations, the role 
of anoctamins in cancers is not straightforward, and it does not seem to have only 
one mechanism. Elevated ANO1 expression has been shown in many cancers (Liu 
and others 2012; Zeng and others 2019). Consistently, ANO1 inhibition has been 
shown to reduce cell proliferation (Guan and others 2016; Seo and others 2018). 
Other cancer mechanisms related to low ANO1 expression levels are the induction 
of apoptosis (Song and others 2018) and retarded cell migration (Jacobsen and others 
2013; Ruiz and others 2012). ANO6 was also proposed to increase migration (Ruiz 
and others 2012) and invasion abilities by inducing extracellular signal-regulated 
kinase (ERK) localization in the nucleus (Xuan and others 2019). However, ANO6 
has also been shown to promote apoptosis instead of reducing it (Forschbach and 
others 2015; van Kruchten and others 2013). 
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2.6.2 ANO7 
The genomic location of ANO7 2q37.3 has been associated with PrCa susceptibility 
in linkage analysis (Cropp and others 2011) and GWAS (genome-wide association) 
studies (Schumacher and others 2011).  
The anoctamin 7 (ANO7) gene was reported for the first time in 2004 by Bera 
and others as ‘a new gene expressed in prostate’ (NGEP) (Bera and others 2004). 
Other names for the gene are transmembrane protein 16G (TMEM16G), PCANAP5, 
IPCA-5 and Dresden-transmembrane protein of the prostate (D-TMPP). ANO7 gene 
expression is also suggested to be regulated by androgens (Kiessling and others 
2005), and the expression seems to be lower in PrCa metastases than in primary 
tumours (Chandran and others 2007). 
ANO7 encodes two mRNA isoforms that are translated into proteins: ANO7L 
(long form) is a polytopic membrane protein that contains all 25 exons, and ANO7S 
(short form) is a small cytoplasmic protein that contains only the first four exons 
(Bera and others 2004; Katoh 2004) (Figure 5). 
Figure 5.  Structure of the ANO7 gene and the two transcripts. The grey boxes represent its 25 
exons. Modified from http://atlasgeneticsoncology.org/Genes/GC_ANO7.html. 
ANO7L has been reported to be located in the plasma membrane (Bera and others 
2004; Das and others 2007), endoplasmic reticulum (ER) (Duran and others 2012) 
and Golgi apparatus (Das and others 2007). The protein is found in lipid rafts, which 
are structures of the cell plasma membrane (Dubois and others 2015). 
Very little is known about the function of ANO7. While the studies by Tian and 
Schreiber demonstrated that ANO7 creates chloride ion currents (Schreiber and 
others 2010; Tian and others 2012), Duran and Suzuki (Duran and others 2012; 
Suzuki and others 2013) showed that ANO7 does not have an ion channel function. 
Instead, Suzuki and others showed that ANO7 works as a phospholipid scramblase, 
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which flips the phospholipids of the plasma membranes from inner leaflet to the 
outer leaflet (Suzuki and others 2013).  
At the protein level, low ANO7 has been reported to be associated with high-
grade PrCa (Mohsenzadegan and others 2013). However, another study by Das and 
others did not observe any difference in protein expression between high- and low-
grade tumours but demonstrated decreased expression in tumours compared to 
benign prostate tissue (Das and others 2007). 
Interestingly, ANO7 has been suggested as a suitable target for PrCa T cell 
therapy. Cereda and others found that ANO7 could act as a target for a PrCa vaccine 
(Cereda and others 2010). 
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3 Aims 
Currently, there are many unmet needs in PrCa diagnostics and in deciding the 
proper treatment for each patient. Although the clinical nomograms combined with 
PSA testing are considerably good in identifying PrCa patients who have already 
progressed, additional predictive biomarkers are still needed to discriminate indolent 
and aggressive cases at earlier stages of PrCa. PrCa is known to have a strong genetic 
background, but the genetic changes identified so far do not explain the susceptibility 
to aggressive PrCa. 
The specific aims of the thesis were as follows: 
1. To study the ANO7 gene, which is located in the chromosomal region
2q37.3, a region that has been associated with predisposition to PrCa in
GWAS and linkage analyses
2. To find specific germline variants in ANO7 that predispose to prostate cancer
3. To survey whether the detected ANO7 germline variants are associated with
the aggressive type of PrCa
4. To examine whether ANO7 variants could be useful in prostate cancer
diagnostics or in planning the most suitable treatment for prostate cancer
patients
5. To investigate ANO7 protein-protein interactions to learn more about the
mechanisms of ANO7 in prostate cancer
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4 Materials and Methods 
Numbers I, II and III after each heading indicate the article in which the sample 
material or method was used. 
4.1 Study material 
4.1.1 Ethical approval and informed consent (I, II) 
Informed consent was obtained from all the participants in the studies. The research 
was approved by the Institutional Review Boards of the Turku and Tampere 
University hospitals. 
4.1.2 PrCa patient material 
The patient characteristics are described in detail in Table 2. 
4.1.2.1 PSA screening cases (I) 
The 559 blood-derived DNA samples were obtained from affected patients who were 
diagnosed with PrCa in a Finnish PSA screening study FinRSPC (Finne and others 
2003). 
4.1.2.2 Clinical PrCa cases (I) 
The unselected PrCa cases were collected from Tampere and Turku University 
Hospitals. In total, 844 diagnostic blood DNA samples were received from Tampere, 
and 200 PrCa blood samples originated from the Turku Prostate Cancer Consortium 
(TPCC) study. The unselected cases were diagnosed similarly as any new PrCa, but 
not in a predefined screening program. All TPCC patients additionally underwent 
radical prostatectomy.  
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ARTICLE II 
Auria Biobank, 
Turku, Finland 
(docetaxel as 
the first-line 
therapy for 
CRPC) n=110 
67 (62-72) 
42 (47%) 
47 (53%) 
21 
18 (8.6-81) 
PROSTY study 
(treatment 
cohort) n=98 
65 (61-71) 
21 (24%) 
65 (76%) 
12 
92 (38 - 230) 
FinRSPC 
screening 
samples 
n=559 
67 (63-69) 
384 (69%) 
169 (31%) 
6 
6.6 (4.6-11) 
ARTICLE I 
Tampere 
University 
Hospital PrCa 
samples 
(diagnostic 
samples), 
n=844 
59 (56-63) 
625(81%) 
146 (19%) 
73 
7.9 (5.2-14) 
Turku 
Prostate 
Cancer 
Consortium 
(TPCC) 
(treatment 
cohort), 
n=200 
63 (59-68) 
162 (81%) 
37 (19%) 
1 
8.5 (5.7-14) 
Familial 
cases, 
index 
patients, 
n=142 
66 (60-72) 
72 (81%) 
17 (19%) 
53 
13 (6.9-38) 
Auria 
Biobank, 
Turku, 
Finland 
(docetaxel-
treated 
patients), 
n=61 
64 (61-68) 
6 (22%) 
21 (78%) 
34 
3.1 (0.47-13) 
PROSTY 
study 
(treatment 
cohort), n=22 
64 (59-70) 
3 (18%) 
14 (82%) 
5 
60 (30-120) 
Median 
(IQR) 
≤7 
≥8 
Missing 
data 
Median 
(IQR) 
Age at 
diagnosis, 
years 
Gleason, 
n(%) 
PSA at 
diagnosis 
(ng/mL) 
Table 2.    Patient characteristics in the articles I and II. N=number, IQR=interquartile range. In the PROSTY (I, II) and the Auria (II) cohorts PSA 
levels have been measured before docetaxel treatments
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4.1.2.3 Familial cases (I) 
The affected familial cases included 142 index patients who had the most severe 
PrCa within the family (one patient per family). This cohort was separate from the 
screening cases and TPCC cohort. Germline DNA was isolated from blood. 
4.1.2.4 CRPC cases (I, II) 
CRPC cases were analysed in articles I and II. All CRPC cases originated either from 
the randomized, registered, prospective trial PROSTY (NCT00255606) 
(Kellokumpu-Lehtinen and others 2013) or from Auria Biobank (Turku, Finland).  
In article I, the PROSTY samples (n=22) that were used in targeted ANO7 
sequencing were formalin-fixed paraffin-embedded (FFPE) prostatectomy samples. 
The Auria samples used in genotyping were matched blood and prostate tissue pairs 
from 61 CRPC patients, who had been treated with docetaxel (not necessarily as the 
first-line therapy for CRPC). The prostate tissue samples were primary PrCa, which 
later developed CRPC.  
In article II, in addition to the 22 samples that were used in the first article, we 
also included all 76 PROSTY prostate biopsies that had enough material for DNA 
extraction. The total number of PROSTY DNA samples was 98. The samples were 
taken from the primary cancer that later developed CRPC. The Auria samples were 
selected from the Turku University Hospital patient registry (between 2007 and 
2018) so that they had similar inclusion and exclusion criteria as those in the 
PROSTY study (Kellokumpu-Lehtinen and others 2013). The Auria samples were 
selected retrospectively from the patient records, and the sample was requested from 
the Auria biobank if the patient received first-line docetaxel treatment for mCRPC, 
the patient had at least two cycles of docetaxel, and there was a sample available in 
Auria biobank. Early chemohormonally treated patients who had less than 90 days 
between the initiation of ADT and docetaxel administration were excluded. Thirty-
one Auria samples overlapped with those used in article I. The additional 79 cases 
were blood samples or FFPE material from tissues other than prostate (n=62) and 
FFPE prostate tissue (n=17), making the total number of patients 110. The FFPE 
DNA samples originating from tissues other than the prostate were sourced from 
lymph node (n=19), skin (n=13), seminal vesicle (n=2), appendix (n=2), colon (n=2), 
liver (n=2), duodenum (n=2), gastric antrum (n=1), spinal canal (n=1), vertebral 
column (n=1), tongue (n=1), upper jaw (n=1), synovium, (n=1), lip (n=1), urinary 
bladder (n=1), and penis (n=1).  
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4.1.2.5 Non-Finnish validation cohorts (I) 
The Swedish cohorts STHM2 (Nordström and others 2014) and PROCAP (Szulkin 
and others 2012), having 4,561 individuals (3,132 cases and 1,429 controls) and 669 
patients, respectively and the Norwegian CONOR cohort (Naess and others 2008; 
Szulkin and others 2015) of 1,455 PrCa patients who were genotyped as part of the 
ONCOARRAY study were used for validation. The number of the patients who died 
of PrCa were 96 in STHM2, 225 in PROCAP and 764 in the CONOR cohort, 
respectively. DNA originated from blood in all cases and controls. 
4.1.3 Control samples (I) 
The set of non-affected control males consisted of 12 samples from the Finnish Red 
Cross and 122 from the Department of Medical Genetics (Genomics, Laboratory 
Division, Turku University Hospital, Turku, Finland) and 1,577 samples from the PSA 
screening study (Finne and others 2003). The males from the PSA screening study were 
found to have a normal PSA level (<1.4 ng/mL), whereas the other samples were chosen 
by age and sex among the population, and some of them may have had undiagnosed 
PrCa. Moreover, 522 family unaffected members from 43 families (relatives of the 
‘Familial cases’) were used to study the segregation of the variants and PrCa.  
4.1.4 PrCa cell lines (I, III) 
In article I, the whole ANO7 gene was sequenced from seven PrCa cell lines, DuCaP, 
LaPC, LNCaP, PC3, VCaP, DU145, and 22Rv1, as well as from the EP156T and 
PrEC cell lines, which were derived from normal prostate (Table 3.). The source of 
these cell lines was The American Type Culture Collection (ATCC). 
Table 3. Prostate cell lines used in the articles. 
CELL LINE SOURCE 
ANDROGEN 
DEPENDENCE/INDEPENDENCE 
DUCAP Dura mater metastasis Dependent 
LAPC Xenograft from lymph node metastasis Dependent 
LNCAP Lymph node Dependent 
VCAP Vertebral metastasis Dependent 
PC3 Vertebral metastasis Independent 
DU145 Brain metastasis Independent 
22RV1 Xenograft Dependent 
EP156T Normal prostate epithelium Dependent 
PREC Normal prostate epithelium Dependent 
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The LNCaP cell line was used in functional studies in article III because it expresses 
endogenous ANO7 mRNA (Bera and others 2004; Mohsenzadegan and others 2015). 
4.1.5 Databases (I) 
RNAseq data were acquired from TCGA research network, cBio Cancer Genomics 
Portal (Cerami and others 2012) and microarray data from the Oncomine database 
(Rhodes and others 2004). 
4.2 Methods 
4.2.1 DNA and RNA isolation (I, II) 
Genomic DNA from blood samples was extracted with a Nucleon BACC3 kit (GE 
Healthcare Life Sciences) according to the protocol of the manufacturer. Isolated 
DNA was eluted into TE buffer and stored at -80°C. 
DNA and RNA from fresh prostate tissue were isolated with a Nucleospin kit 
(Macherey Nagel) according to the protocol of the manufacturer. Both DNA and 
RNA were extracted from the same piece of tissue. 
For FFPE tissue DNA isolation, a QIAamp DNA FFPE Tissue Kit (Qiagen) was 
used, and the extraction was performed according to the kit’s instructions. 
4.2.2 Targeted NGS (I) 
An Illumina Truseq Custom Amplicon library (Illumina) was designed to cover all 
25 ANO7 exons (from the hg19 assembly) with 97% gene coverage. The amplicon 
size was 175 bp, and 250 ng of DNA was used for sequencing (targeting and library 
preparation). The samples were prepared for MiSeq sequencing machine (Illumina). 
Sequencing was conducted on 22 mCRPC samples (tumour DNA) and 50 TPCC 
PrCa samples (blood DNA) as well as on 14 unaffected male controls (blood DNA). 
The sequencing results were analysed with an in-house pipeline that included 
quality control with FastQC and adapter sequence trimming with Cutadapt, and the 
sequences were aligned to the hg19 reference genome using the Burrows-Wheeler 
Aligner. The files were then converted from SAM files to BAM files with the 
SAMtools package, BAM files from the same sample were merged, and duplicate 
reads were annotated with the Picard tools software suite. The variant call step was 
conducted with GATK using HaplotypeCaller, which produced gVCF files, which 
were further annotated using ANNOVAR. 
The ANO7 variants that had a deleterious impact according to the ‘in silico’ 
analysis tool CADD, were rare globally (minor allele frequency <0.05) and 
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overlapped in previous familial PrCa studies were selected for validation in larger 
sample cohorts. 
4.2.3 Genotyping (I, II) 
For genotyping, ready-made TaqMan® SNP Genotyping Assay primers and probes 
(Bio-Rad) were used. The reactions were prepared according to the manufacturer’s 
protocol using 10 ng of DNA, and the total reaction volume was 25 µl. The reactions 
were analysed with a CFX96 Touch Real-Time PCR Detection System (Bio-Rad) 
using the PCR programme recommended by the TaqMan protocol. In addition to the 
samples, all runs included a non-template control, positive control (heterozygous 
SNP carrier verified with Sanger sequencing) and negative control (SNP non-carrier 
verified with Sanger sequencing). The results were analysed with CFX Manager 3.1 
software (Bio-Rad). Ten percent of the samples were randomly selected for Sanger 
validation. To investigate whether the ANO7 rs77559646 and rs148609049 variants 
were mutated in tumours or if the variants are always in the germline, we analysed 
matching blood and prostate tissue samples from Auria cohort samples. 
4.2.4 Statistical analyses (I, II) 
In article I, all the analyses were performed with R version 3.2.2. Case-case analyses 
were performed to study the possible variant impact on PrCa susceptibility. To 
investigate the variant association with aggressiveness, the patients were divided into 
aggressive and non-aggressive groups for case-case analysis. In our studies, 
aggressive PrCa was defined according to the International Consortium for Prostate 
Cancer Genetics (ICPCG) criteria (Hunter 2017; Schaid and others 2006). The 
disease was classified as aggressive if PSA was ≥ 20 ng/ml, the Gleason grade was 
≥ 8, the patient had metastatic disease, or PrCa was the cause of death. Differential 
expression was analysed the publicly available datasets from TCGA and Oncomine. 
In the analysis, we compared ANO7 expression in normal and cancerous prostatic 
tissues. Expression quantitative trait loci (eQTL) analysis was performed for the 
rs77559646 variant in the Camcap and Stockholm datasets and for RNAseq results 
that originated from Finnish PrCa tumour RNAseq experiments (TPCC RALP 
samples). Kaplan-Meier and multivariate analyses were performed to investigate the 
association between patient survival and ANO7 variants or ANO7 expression level. 
The missing endpoints were censored from the survival analyses. 
In article II, the statistical analyses were performed with SAS JMP Pro 14 version 
(SAS Institute). Kaplan-Meier analyses were performed for progression-free 
survival (PFS) and overall survival (OS). The PFS was defined from the date of 
initiation of docetaxel to the date of biochemical or radiological progression or 
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patient death. The radiographic response and progression were assessed following 
the RECIST 1.1 criteria (Eisenhauer and others 2009), whereas the criteria for 
biochemical response and progression were the same as those in the PROSTY study 
(Kellokumpu-Lehtinen and others 2013). OS was calculated from the date of 
docetaxel treatment initiation to the date of death. 
4.2.5 BioID (III) 
The principle of the Proximity-dependent biotin identification (BioID) method, which 
was originally created by Roux and others (Roux and others 2013), is visualized in 
Figure 6. In the method, the gene of interest is fused together with the biotin ligase 
BirA*. The fusion protein is expressed in cells, and BirA* labels all proteins that are 
in close proximity with the protein of interest. The biotin labelled proteins can then be 
purified with streptavidin beads and identified with mass spectrometry. The method 
allows the detection of both stable and transient interactions. 
4.2.5.1 Cloning (III) 
The BioID plasmid used was the pcDNA3.1 MCS-BirA(R118G)-HA plasmid 
(Addgene plasmid #36047; http://n2t.net/addgene:36047; RRID:Addgene_36047) 
(Addgene). The ANO7L insert was PCR-amplified from the pNGEP-L plasmid 
(insert size 2,799 bp). DH5 alpha competent cells were transformed with ANO7L 
and the control construct (the same plasmid without the ANO7L insert). The ANO7 
insert was Sanger sequenced to verify the correct sequence. 
An ANO7 construct that carried carboxy-terminal V5 and His-tags was used as 
a control for immunohistochemical protein-protein interaction validation staining. 
4.2.5.2 Cell culturing, transfection and addition of biotin 
Lymph node carcinoma of the prostate (LNCaP) cells were maintained in RPMI-
1640 medium (Lonza) with inactivated 10% foetal bovine serum, 100 U/ml 
penicillin, 0.1 mg/ml streptomycin and 2 mM ultraglutamine in 5% CO2 at 37°C. 
The cells were plated on Petri dishes and sterile glass cover slips. They were 
transfected with Lipofectamine 3000 (Thermo Fisher Scientific) one day after 
plating with ANO7L-BirA*-HA and BirA*-HA constructs. In parallel, non-
transfected LNCaP cells were grown. The transfection conditions were identical to 
those in Thermo Fisher Scientific’s optimized protocol for the LNCaP cell line. The 
cells were incubated for 24 hours, and 59 µM biotin was added to the transfected and 
non-transfected cells. The cells were rinsed with PBS and lysed in lysis buffer after 
24 hours. The samples were sonicated and rotated at 4°C for 15 minutes. The 
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supernatants were collected after centrifugation, and MyOne Streptavidin (MyOne 
Streptavidin C1 Dynabeads, 10 mg/ml, Invitrogen) beads were added to the lysates. 
After rotating the samples with the beads overnight, the beads were washed with 
BioID wash buffer and stored. Western blot samples were collected from the cell 
debris and purified beads and mixed with Laemmli buffer. The whole protocol was 
repeated three times to obtain a final number of replicates of six. 
Figure 6. The principle of BioID purification. The transfected ANO7L-BirA*-HA fusion protein 
localizes on the plasma membrane (PM), and BirA* ligates biotin to all proteins 
interacting with ANO7L. The cells are then lysed, and streptavidin beads are used in 
collecting the biotinylated proteins. The proteins are then eluted and analysed with mass 
spectrometry. 
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4.2.5.3 Transfection of the dual-staining validation samples 
For validation with dual staining, LNCaP cells were transfected with ANO7L-
BirA*HA, BirA*-HA and ANO7L-His constructs. The cells were not treated with 
biotin. 
4.2.5.4 Protein identification and filtering 
The purified BioID samples were analysed at the Turku Proteomics Facility (Turku 
Bioscience, Turku, Finland) with an LC-ESI-MS/MS nanoflow HPLC system (Easy-
nLC 1200, Thermo Fisher Scientific). The proteins were identified with Proteome 
Discoverer 2.2 software (Thermo Fisher Scientific). The required number of peptide-
spectrum matches was two when filtering the data by peptide spectrum matches per 
protein. The list of proteins was compared to the common background of the BioID 
method (Roux and others 2013) and CRAPome database (https://www.crapome.org). 
4.2.5.5 Enrichment analysis 
The enrichment analysis for the identified proteins was performed with the Gene 
Ontology (GO) ‘cellular component’ enrichment tool. All proteins that passed the 
filtering described above were used in the analysis. The cut-off value for the false 
discovery rate (FDR) was <0.0001 with a fold enrichment >2. 
4.2.5.6 Western blot 
Western blot analysis was performed to validate that the fusion protein was the 
correct size and not degraded in the cells. Protein samples that were collected during 
the BioID protein collection protocol were run on 10% SDS-PAGE gels, and the 
fusion proteins as well as the biotinylated proteins were detected according to the 
protocol by Roux and others (Roux and others 2013). The biotinylated proteins were 
detected with Pierce™ High Sensitivity Streptavidin-HRP (21130, Thermo Fisher 
Scientific). Primary antibodies against the HA tag (H6908, Sigma-Aldrich) and 
HRP-conjugated anti-rabbit IgG (sc-2054, Santa Cruz Biotechnology) secondary 
antibodies were used in the detection of ANO7L-BirA*-HA and control BirA*-HA 
fusion proteins. 
4.2.5.7 Immunofluorescence staining and imaging 
The transfected LNCaP cells that were grown on sterile glass coverslips rinsed with 
PBS, fixed with PFA-PBS and permeabilized with Triton X-100. ANO7L-BirA*-
HA was first verified to localize correctly near the plasma membrane. Additionally, 
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the biotinylation was verified to localize near ANO7L. For this purpose, antibodies 
against the HA tag and streptavidin-conjugated antibodies were used. After choosing 
the proteins for the dual staining colocalization test, ANO7L-BirA*-HA and 
ANO7L-His (and the BirA*-HA control) were stained in parallel with the 
endogenous interacting proteins. All antibodies used are listed in Table 4. The fusion 
proteins were verified with a Nikon Eclipse Ni-U upright fluorescence microscope 
(Nikon Instruments, Inc.) and the dual staining was visualized with a STED 
microscope (Abberior Instruments). ImageJ (NIH, version 18.0) was used for 
analysing the figures and generating fluorescence intensity profiles. 
Table 4.  Antibodies used in the BioID validation. 
ANTIBODY Source 
Streptavidin-Alexa Fluor™ 488 
conjugate 
S32354 (Thermo Fisher Scientific) 
Anti-HA tag antibody H6908 (Sigma-Aldrich) 
Anti-6X His tag® antibody ab18184 (Abcam) 
Mouse monoclonal [16B12] to HA 
tag 
ab130275 (Abcam) 
Anti-HSPA1A ab79852 (Abcam)  
Anti-AP2B1 ab220778 (Abcam) 
Anti-COPG2 NBP2-55178 (Novus Biologicals)  
Anti-SND1 ab65078 (Abcam) 
STAR RED, goat anti-rabbit IgG 2-0012-011-9 (Abberior Instruments GmbH) 
STAR 580 anti-mouse IgG 2-0002-005-1 (Abberior Instruments GmbH) 
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5 Results 
5.1 PrCa patients frequently have ANO7 
mutations, and the types of variants vary 
between sample cohorts (I) 
To identify the potential pathogenic ANO7 variants, the whole gene from 14 
unaffected males, 50 unselected RALP PrCa patients, 22 CRPC patients and 9 PrCa 
cell lines was sequenced. A total of 215 variants were found in the ANO7 gene in the 
targeted whole gene sequencing. One was annotated as stop-gain mutation, seven 
were frameshift mutations, 16 were missense mutations, seven were mutations of the 
splice region, 64 were intronic mutations, 23 were non-coding mutations, four were 
synonymous mutations, and six were 3’UTR mutations. In addition, the variant call 
reported 44 variants downstream and 43 upstream of the ANO7 gene. Control males 
did not have any splice site variants, unlike the PrCa cell lines, RALP patients and 
CRPC patients. Stop-gain variants were observed in CRPC and RALP patients but 
not in the controls or the PrCa cell lines. The CRPC patients more frequently had 
missense variants than the other groups. The PrCa cell lines, in turn, more frequent 
had frameshift variants than any other group (Figure 7). 
Among the variants, we selected the three SNPs that were not observed in the 
controls but were seen in at least two CRPC patients, had a low minor allele 
frequency in the Finnish population (<5% in the ExAC database, 
http://exac.broadinstitute.org) and were deleterious according to mutation prediction 
programmes (combined annotation‐dependent depletion [CADD] score >10). The 
variants were a stop-gain variant, rs148609049 (C>T), in exon 1, a splice 
site/missense variant, rs77559646 (G>A), in intron/exon 4 and a missense variant, 
rs181722382 (T>C), in exon 25. The rs181722382 variant was so rare in genotyping 
results (<1%) that it was excluded from the more detailed analyses. 
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Figure 7.  Variant types in targeted ANO7 sequencing. 
The variants rs148609049 and rs77559646 were genotyped in 1,679 PrCa patients 
and 1,711 controls. When observing different PrCa patient cohorts and unaffected 
control males, the rs77559646 frequency was the lowest in unaffected males (7.4%), 
followed by patients who were diagnosed in the screening trial (9.9%), clinical cases 
(10.5%), and familial cases (11.9%), and the greatest in docetaxel-treated CRPC 
patients (13.7%) (Figure 8.). The frequency of rs148609049 was relatively similar 
in all cohorts (7.2%, 5.9%, 7.6% and 7.6%, respectively) except in docetaxel-treated 
patients, in whom there were slightly more variant carriers (9.2%) (Figure 8.). The 
rs77559646 variant was also detected in the 22Rv1 PrCa cell line. 
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With matching blood and prostate tissue samples from the same patient, we 
showed that the variants already existed in the germline. Furthermore, the fact that 
the variant distribution in the sample was always approximately 0, 50 or 100 % 
suggested that the variants were not somatic mutations. 
Figure 8.  Rs77559646 and rs148609049 variant frequencies in different patient cohorts and 
unaffected males. The dark grey columns show rs77559646 carriers and the light grey 
columns rs148609049, respectively. 
5.2 ANO7 variants are associated with PrCa 
susceptibility and aggressiveness (I) 
5.2.1 rs77559646 predisposes to PrCa in Finnish and 
Swedish males 
According to the gnomAD (Genome Aggregation Database, 
https://gnomad.broadinstitute.org), the global minor allele frequencies for the 
variants rs148609049 and rs77559646 are 0.006 and 0.01, respectively, and for the 
Finnish population, they are 0.036 and 0.026, respectively. When transforming these 
numbers into the number of variant carriers, our results corresponded well to these 
proportions: 6.8% for rs148609049 and 6.9% for rs77559646. 
We observed a statistically significant difference between the rs77559646 
variant frequency in PrCa patients and that in unaffected males (OR 1.39; 95% CI 
1.09-1.78), indicating that the variant predisposes to PrCa. A similar effect was 
observed in the Swedish cohort STHM2 (Nordström and others 2014) (OR 1.36; 
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95% CI 1.06-1.75). Rs148609049, in turn, was not associated with PrCa risk in any 
cohort. 
5.2.2 rs148609049 and rs77559646 are enriched in PrCa 
families 
The variants rs148609049 and rs77559646 were analysed in 142 PrCa families 
(664 family members in total). Both variants were frequently present in the 
investigated families (21/142 [14.8%] families carried the rs148609049 variant, 
and 25/142 [17.6%] carried the rs77559646 variant), showing an enrichment in the 
familial cases. However, in some cases, the index patient did not carry the variant, 
and some other family member(s) did. Eight families (5.6%) carried both variants. 
The variants were inherited separately in these families, which indicates that they 
are not in the same haplotype. Neither of the variants had complete segregation 
with the disease. 
5.2.3 rs77559646 is associated with an aggressive PrCa 
phenotype 
In case-case analyses, we compared the variant frequencies of non-aggressive PrCa 
cases and aggressive cases to investigate whether the variants were associated with 
an aggressive phenotype. The disease was classified as aggressive if one of the 
following criteria was met: PSA ≥20 ng/ml, Gleason score ≥8, presence of 
metastases, or PrCa was lethal (Schaid and others 2006). Rs77559646 was more 
common in the aggressive cases than in nonaggressive cases (genotype test p=0.04), 
whereas rs148609049 was not (genotype test p=0.68). Among the individual clinical 
variables, rs148609049 carriers had more other cancers than the non-carriers, and 
their cause of death was more frequently PrCa than other reasons (not statistically 
significant). In turn, there was a trend between rs77559646 and early-onset disease 
(not statistically significant). An enrichment in more aggressive cases was also seen 
when observing the frequency of the variant carriers in the different sample sets 
(Figure 8). 
5.2.4 rs148609049 is related to decreased survival time 
among PrCa patients 
Although the variant rs148609049 was not more common in aggressive PrCa cases 
than in nonaggressive PrCa cases, it correlated with poor survival in Kaplan-Meier 
log-rank analysis (p=0.049). In contrast, rs77559646, which was associated with 
aggressiveness, did not affect the survival time. The variants’ effects on survival 
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were also assessed together with age, PSA and Gleason score. A Cox regression 
model revealed that rs148609049 had an independent unfavourable influence on 
patient survival (HR 1.56, 95% CI 1.03-2.37). Other significant factors in the model 
were age at diagnosis (HR 1.06, 95% CI 1.034-1.08) and Gleason score (HR 4.7, 
95% CI 3.61-6.12). 
5.3 rs77559646 is associated with elevated ANO7 
mRNA expression (I) 
eQTL analysis for rs77559646 variant carriers and non-carriers indicated that the 
mutation was associated with an increased ANO7 expression level in prostate tumour 
tissues. The association between the variant and mRNA expression was studied in 
three PrCa datasets. The first dataset included whole transcriptome sequencing data 
from the Finnish RALP samples (Turku Prostate Cancer Consortium), and the p-
value for the eQTL test was 0.0086. The other two sample sets were from data from 
the Camcap and Stockholm cohorts that originated from Expression BeadChip-based 
transcriptional profiling analysis (Whitington and others 2016), and the p-values for 
their eQTL were 2.53*10-6 and 1.53*10-13, respectively. 
5.4 rs77559646 is a prognostic marker for good 
docetaxel response (II) 
Because the rs77559646 variant was observed to be associated with aggressive PrCa 
but there was no association with worse survival, we investigated whether docetaxel 
therapy would provide a benefit to variant carriers. Of the rs77559646 SNP carriers, 
77.7% had a biochemical response to docetaxel treatment, whereas only 58.4% of 
the non-carriers responded (Figure 9). However, the difference between the groups 
was not statistically significant (OR=2.50; 95% CI 0.791‒7.87; p=0.12). 
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Figure 9.  Biochemical response (PSA response) to docetaxel treatment among the rs77669646 
carriers and non-carriers. 
The docetaxel treatment-associated PFS times and the impact of rs77559646 on PFS 
were analysed in the PROSTY and the Auria mCRPC patient cohorts. As shown in 
Figure 10, the patients who did not have the rs77559646 variant had quite similarly 
shaped PFS curves in both cohorts. The PFS curves of the carriers, in turn, differed 
from those of the non-carriers. The PROSTY patients had a statistically significant 
difference between the carriers and non-carriers (p=0.005), but the Auria patients did 
not have significantly different PFS times when comparing the carriers and the non-
carriers (p=0.09). 
In the OS analysis, the only group that differed in survival time was the PROSTY 
rs77559646 variant carriers. The difference between the PROSTY carriers and non-
carriers was statistically significant (p=0.003), whereas it was not significant for the 
Auria cohort (p=0.9). Notably, the non-carriers in the Auria cohort survived longer 
than the non-carriers in the PROSTY cohort. 
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Figure 10.  Kaplan-Meier survival plots for PFS and OS in the Auria (black lines) and PROSTY (grey 
lines) patient cohorts. 
Cox regression analysis (Figure 11) was performed to model the impact of the 
rs77559646 variant and important clinical variables: Gleason score, PSA value at 
diagnosis and the time from diagnosis to docetaxel treatment initiation. The whole 
model was statistically significant for the PROSTY cohort (p<0.0001) but not for 
the Auria cohort (p=0.057). However, in both models, rs77559646 was a statistically 
significant variable that was able to predict PFS (PROSTY HR 3.9 [95% CI 1.5‒12], 
p=0.0027; Auria HR 2.4 [95% CI 1.1-6.1], p=0.024). There were no other 
statistically significant variables in the Auria cohort. In the PROSTY cohort, the 
Gleason score was also a statistically significant variable in the Cox regression 
model (HR 1.8 [95% CI 1.0‒3.1], p=0.04). 
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Figure 11. Cox regression analysis for progression-free survival time (PFS) after docetaxel 
treatment in PROSTY and Auria patient cohorts. The variables in the models are the 
rs77559646 variant, PSA, time from diagnosis to docetaxel treatment and Gleason 
score ≥8. PFS= progression-free survival; HR=hazard ratio; 95% CI= 95% confidence 
interval; PSA= prostate-specific antigen. 
5.5 ANO7 is highly expressed in PrCa, and the 
increased level predicts poor prognosis (I) 
5.5.1 ANO7 is highly expressed in prostate tissue, and its 
expression is elevated in PrCa vs. benign prostate 
tissues 
ANO7 expression was monitored across normal and cancer tissues in the Oncomine 
database (Rhodes and others 2004). ANO7 mRNA levels were higher in the prostate 
than in other tissues in both comparisons. Moreover, ANO7 expression was elevated 
in PrCa versus benign prostate tissues in the TCGA prostate (Cerami and others 
2012) and Arredouani prostate (Arredouani and others 2009) cohorts (p=0.00004). 
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5.5.2 Elevated ANO7 expression is associated with 
shortened survival time among PrCa patients 
To study whether ANO7 mRNA expression has an impact on PrCa patient survival, 
Kaplan-Meier and Cox regression analyses were conducted. The TCGA database 
prostate cancer cohort (Cerami and others 2012) was used in survival analysis, and 
the patients were divided into ‘higher’ and ‘lower’ expression groups. The higher 
and lower levels were defined according to the mean expression value of the whole 
data set. The endpoint in this study was the death of the patient. High ANO7 
expression was strongly associated with poor survival among PrCa patients (hazard 
ratio 18.41; Cox p= 0.0255). 
5.6 ANO7 interacts with proteins involved in 
cellular vesicle trafficking, the nuclear lumen, 
chromosomes, sites of DNA damage and the 
Arp2/3 complex (III) 
The long form of ANO7 physically interacted with 64 proteins. The proteins were 
included in the list of interacting proteins if they were specific for the ANO7 
construct and not found to interact with a control construct that lacked the ANO7 
insert. These proteins were compared with the GO ‘cellular component’ enrichment 
tool, and the analysis revealed six partly overlapping components: ‘Vesicle’ (fold 
enrichment 2.54, FDR 9.26x10-6), ‘Extracellular exosome’ (fold enrichment 3.77, 
FDR 2.57x10-7), ‘Nuclear lumen’ (fold enrichment 2.37, FDR 5.51x10-5), 
‘chromosome’ (fold enrichment 5.50, FDR 2.67x10-7), ‘site of DNA damage’ (fold 
enrichment 28.78, FDR 1.15x10-6) and ‘Arp2/3 complex’ (fold enrichment >100, 
FDR 1.72x10-5) (Figure 12). 
ANO7 was validated to colocalize with four proteins identified with mass 
spectrometry: Heat shock 70 kDa protein 1A (HSPA1A), COPI coat complex 
subunit gamma 1 (COPG2), AP-2 complex subunit beta (AP2B1) and 
Staphylococcal nuclease domain-containing protein 1 (SND1) (Figure 13). 
In Western blot analysis, ANO7L-BirA*-HA and the BirA*-HA control were 
confirmed to be the correct size (141 kDa and 36 kDa, respectively), and 
biotinylation of proteins was detected when the biotin ligase was present in the 
cells. 
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Figure 12. ANO7- interacting proteins divided into categories according to the GO cellular 
localization enrichment results. In total, 64 proteins were found to interact with ANO7, 
and they clustered into six cellular localizations, which were partly overlapping. 
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Figure 13. Double staining for overexpressed ANO7 and the identified interaction partners. The 
green colour shows the localization of transfected ANO7L-His, and the interacting 
proteins are shown in purple. 
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6 Discussion 
6.1 ANO7 as a biomarker in PrCa 
The ANO7 variant rs148609049 was associated with poor PrCa patient survival in 
this study. Since the variant resides in the very first exon and creates a premature 
stop codon, it would be expected that no ANO7 protein is produced from the variant 
allele because the transcript is degraded by the nonsense-mediated decay (NMD) 
mechanism, which mainly destroys all transcripts that have a premature stop codon 
far from the real translation end site (Amrani and others 2006). We did not observe 
any impact of the variant on the mRNA expression level, but it still may have an 
impact on the protein level. 
The variant rs77559646, in turn, was related to elevated ANO7 mRNA 
expression, and it was demonstrated to be associated with PrCa susceptibility and 
aggressive disease. The ‘in silico’ prediction suggested that rs77559646 would 
disrupt the splicing of the ANO7 long form or alternatively cause an amino acid 
change in the ANO7 short transcript. As the function of the soluble short form is 
unknown, it is difficult to predict its impact on protein function. However, the long 
form is likely degraded by the NMD mechanism. In normal cells, the level of 
functional protein would then be decreased. However, the NMD mechanism is 
known to be dysfunctional in cancer cells (Hu and others 2017), which can lead to 
the accumulation of truncated protein products. If the NMD mechanism is not 
working in the cancer cells, it could mean that the variant carriers would have a 
truncated version of ANO7L. 
Both the rs77559646 and rs148609049 variants, which were found in this thesis, 
predict aggressive PrCa and could be used to separate indolent and aggressive cases. 
Resources could then be better focused on the aggressive cases. At the same time, 
indolent cases could avoid overdiagnosis and treatments that can cause severe side 
effects. Approximately one of ten Finnish PrCa patients carries the rs77559646 
mutation, and one of fifteen carries the rs148609049 mutation, which would mean 
that there are approximately 500 and 300 PrCa affected variant carriers diagnosed 
each year, respectively. ANO7 germline mutation detection can provide new tools 
for PrCa diagnostics and treatment selection. This test would add value to the already 
existing PrCa cancer panels. 
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The finding that the rs77559646 variant did not affect patient survival, although 
it is related to aggressive disease, led us to investigate the efficacy of CRPC 
treatment among carriers and non-carriers. It was shown that variant carriers indeed 
benefit from docetaxel medication more than non-carriers. However, before 
recommending docetaxel instead of other CRPC treatment options, extensive 
prospective studies in which docetaxel, abiraterone and enzalutamide are compared 
are required. Since abiraterone and enzalutamide have been in clinical usage for a 
relatively short time period, performing a similar retrospective study for the benefit 
of second-generation AR-targeted therapies is challenging. 
Germline variants can be tested non-invasively from a blood draw. Compared to 
other available biomarkers, germline variant detection is sensitive, reliable, and 
immutable over time, and the signature does not vary between distinct cancers. Other 
detection methods are still useful in monitoring treatment effectiveness. Thus far, the 
only germline mutations that have been reported to have prognostic value in 
separating aggressive cases from indolent cases are located in DNA repair genes. 
They have been additionally demonstrated to affect CRPC treatment efficacy. PrCa 
patients with germline mutations in DNA repair genes were shown to benefit more 
from PARP  inhibitors than from other mCRPC medications, but standard therapies 
have been shown to be as effective for variant carriers and non-carriers in 
retrospective studies (Mateo and others 2018). Although DNA repair genes are very 
relevant in PrCa progression, and the BRCA2 gene is also related to aggressive PrCa 
(Castro and others 2013), DNA repair genes account for only 15% or less of the PrCa 
cases (Lindström and others 2007). Therefore, there is still a need for additional 
germline biomarkers, such as ANO7 variants. 
6.2 Elevated ANO7 expression is linked to poor 
PrCa patient survival 
This thesis work showed that the ANO7 mRNA expression level was higher in PrCa 
than in benign prostate tissues. Moreover, the increased expression correlated with 
shortened survival time. In a study by Chandran and others ANO7 mRNA expression 
was demonstrated to be downregulated in PrCa metastases compared to the level 
seen in the primary tumour (Chandran and others 2007; Kiessling and others 2005). 
Possibly due to the different detection methods used, the existing literature conflicts 
with our results. Our analyses were performed on RNAseq data, while Kiessling and 
Chandran used probe-based detection that was designed for the last exon of ANO7. 
Therefore, the short ANO7 transcript was not detected in their studies. 
As we have detected all ANO7 transcripts, including those that may not be 
translated into a functional protein, we cannot conclude that high amounts of ANO7 
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protein are seen in PrCa. However, ANO7 clearly has a role in PrCa development, 
which needs to be further investigated. 
6.3 Possible functions of ANO7 in PrCa 
The association studies indicated that ANO7 is biologically relevant in PrCa 
development. However, as so few experiments have been performed on the ANO7 
protein, the mechanism of ANO7 and the effects of the identified variants could only 
be speculated. In particular, the question of why taxanes are effective in treating 
rs77559646 variant carriers has arisen. Is it because taxanes affect rapidly dividing 
and aggressively growing cells? Alternatively, is docetaxel affecting the pathways 
in which ANO7 functions? Since no pathway studies exist for ANO7, we wanted to 
capture ANO7 protein interactions to obtain a better understanding of ANO7 
function. The results indicated that the enriched ANO7 localizations in the GO 
enrichment analysis were vesicles and extracellular exosomes, the nuclear part of the 
cell, and the actin-related protein 2/3 (Arp2/3) complex, which is involved in the 
actin nucleation process. 
Four proteins that were found to interact with ANO7 according to the BioID 
analysis were associated with vesicle trafficking. These proteins were validated to 
localize with ANO7. Two of these proteins, COPG2 and AP2B1, are involved in 
intracellular vesicle trafficking. The two other proteins, HSPA1A and SND1, have 
been found in extracellular vesicles (Bijnsdorp and others 2013; Hosseini-Beheshti 
and others 2012; Soekmadji and others 2017). The colocalization of these proteins 
with ANO7 supports the suggested involvement of ANO7 in vesicle trafficking. 
As many anoctamins, including ANO7, have been shown to have phospholipid-
scrambling activity (Suzuki and others 2013), the vesicle formation process could be 
associated with their scramblase function. The phosphatidylserine phospholipids are 
unevenly distributed in the plasma membrane such that the majority of the 
phosphatidylserines are facing the cytosol. The phospholipid scrambling proteins 
can equalize the distribution between the inner and outer plasma membrane leaflets 
and cause bending in the plasma membrane and initiate cellular vesicle formation 
(Bevers and Williamson 2016). Other possible consequences of scrambling include 
the activation of the cell signalling system (Bevers and Williamson 2016). The 
ANO7 protein has been detected in patient-derived prostate-specific types of 
extracellular vesicles, i.e., prostasomes (Dubois and others 2015; Poliakov and 
others 2009), which again supports our finding that ANO7 interacts with other 
proteins involved in vesicles. As ANO7 has been detected on the apical side of 
epithelial cells (Schreiber and others 2010), it may have a function in producing and 
releasing extracellular vesicles, especially prostasomes, into seminal plasma. In 
cancerous tissues, where the cells lose their polarization, the released prostasomes 
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and prostate-derived exosomes can cause immunological suppression (Lundholm 
and others 2014), promotion of angiogenesis (Ronquist and others 2010) and even 
metastasis formation (Azmi and others 2013). Exosomes are interestingly shown to 
spread docetaxel resistance between PrCa cells (Corcoran and others 2012). This 
would be a possible explanation for the longer docetaxel treatment responses seen in 
ANO7 rs77559646 variant carriers than in non-carriers. The theory warrants further 
investigation, but our finding that ANO7 is involved in vesicle transport is consistent 
with a recent study by Kunzelmann and others, which suggested that anoctamins are 
involved exosome production and membrane curvature modification (Kunzelmann 
and others 2019). 
The Arp2/3 complex, which was among the enriched cellular localizations, could 
be related to intracellular trafficking since the vesicles are transported along the actin 
filaments and microtubules, and it has been demonstrated that the disturbance of the 
complex inhibits vesicle trafficking (Whitlock and Hartzell 2017). The innate 
interaction with nuclear proteins is not as clear since ANO7 has been shown to be 
located in membrane structures such as the plasma membrane (Bera and others 2004; 
Das and others 2007; Dubois and others 2015), ER (Duran and others 2012) and 
Golgi apparatus (Das and others 2007). Prostasomes as well as some other types of 
extracellular vesicles contain chromosomal DNA (Ronquist and others 2012), which 
could explain this association. 
6.4 Study limitations 
In article I, the patient material was limited to Caucasian patients, and in article II, 
all patients were Finnish. Therefore, the observations should be validated 
additionally in other populations. 
In article II, as the variant rs77559646 is relatively rare at the population level, 
only a few carriers were present in our study cohorts. The small number of carriers 
weakens the reliability of the survival analysis results. Additionally, the DNA partly 
originated from FFPE tissues, which are not optimal for germline variant detection 
because, in theory, it is possible that ANO7 mutations could be somatic. However, 
we demonstrated by using blood and tumour tissue pairs from the patients that 
rs77559646 was always detected in the blood if it was present in the tumour sample. 
Moreover, even in prostate tissue, the frequency of the variant was always 
approximately 0%, 50% or 100%. Somatic mutation frequencies do not follow this 
distribution, and this fact is commonly utilized in the computational separation of 
somatic mutations from those in the germline (Sun and others 2018). Furthermore, 
while in the prospective PROSTY cohort the patients were followed on a regular 
basis, the retrospectively collected information was not as accurate because the data 
were collected afterwards, and the follow-up was more irregular. Additionally, the 
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treatment failure time points in the Auria cohort were not as reliable as those in the 
PROSTY cohort. This could also be the reason why the difference in PFS was not 
statistically significant in the Auria cohort. The patients in the PROSTY cohort were 
not treated with second-line abiraterone or enzalutamide, but most of the patients in 
the Auria cohort received one of these therapies. This can mask the effect of 
docetaxel on OS. When comparing the survival plots of the non-carriers in the Auria 
and PROSTY cohorts, the Auria patients had better survival than the PROSTY 
patients. 
In article III, we used transient transfection and only one cell line to show the 
protein-protein interactions. The results represent the ANO7 interactions in PrCa but 
not necessarily the function of ANO7 in normal prostate cells. The reason for testing 
the interactions only in LNCaP cells was that it is the only PrCa cell line that 
endogenously expresses ANO7, and the interacting proteins were thus predicted to 
be present in the cells. In addition, the weakness of the BioID method is that it does 
not require the binding of the protein of interest to the interacting proteins, as the 
biotin ligase labels all proteins that are in close proximity in the cells. To prove that 
the proteins bind with each other, an additional method (for instance, co-
immunoprecipitation) should be implemented. However, the detergents that are 
strong enough to remove the hydrophobic ANO7 from the membrane can also break 
the interaction between the proteins. 
6.5 Future prospects 
There are several additional issues that need to be addressed. What kind of transcripts 
do the normal and mutated ANO7 genes produce? Are all the transcripts translated 
into a protein? Is the produced protein functional? 
To further study the impact of the ANO7 rs77559646 variant on the mRNA and 
protein products, functional studies are still necessary. Because the SNP is predicted 
to weaken normal splicing of ANO7L, a splicing minigene assay (Steffensen and 
others 2014) would be useful in confirming this process. If normal splicing is 
disrupted, the protein product is likely to be destroyed by the nonsense-mediated 
decay mechanism, and no functional product would be formed. In ANO7S, 
rs77559646 leads to an amino acid change, which can change the functionality of 
the protein. By overexpressing the altered ANO7S tagged with a fluorescent label, it 
would be possible to detect whether the protein localization is from that of the normal 
short form. Overexpression studies could also be used to observe the effect of this 
protein product on, for example, cell viability and motility. 
The function of the stop-gain mutation rs148609049 could be tested by silencing 
the whole ANO7 gene. Accordingly, the impact of ANO7 on cancer cells can be 
tested by overexpressing the gene in cell lines. After silencing and overexpressing 
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ANO7, RNAseq could be performed to reveal the pathways that ANO7 influences. 
Furthermore, the impact of overexpression and silencing could be observed with 
invasion, proliferation, migration, and apoptosis assays. After receiving more 
information about ANO7 function, docetaxel (and possibly other CRPC drugs) could 
be added to the cell cultures to investigate how they affect cell growth. 
The impact of ANO7 on vesicle formation could be determined by 
overexpressing and silencing ANO7 and then observing the number of vesicles that 
the cells produce. 
This thesis has pinpointed that ANO7 has potential as a biomarker of PrCa, but 
before utilizing the test in clinical practice, additional functional studies are 
warranted. Some of these studies are already ongoing in our research group, and we 
expect to determine more about ANO7 in PrCa in the near future. 
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7 Conclusions 
 
The ANO7 variants that were found in this thesis work could be used as biomarkers 
for PrCa diagnostics for predicting disease progression. Additionally, the variant 
rs77559646 predicts a good response to first-line docetaxel chemotherapy and would 
therefore be a useful tool in personalized medicine and treatment planning. Before 
the test can be utilized in clinical practice, more extensive prospective studies are 
warranted. However, in combination with PSA, clinical information and other 
germline and somatic gene markers, testing of ANO7 variants could prove useful. 
Although this study revealed that ANO7 could function in vesicle trafficking, 
more information about the mechanisms of action is still needed. 
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